Please login to the form below

Not currently logged in
Email:
Password:

prostate cancer

This page shows the latest prostate cancer news and features for those working in and with pharma, biotech and healthcare.

AZ taps Ionis for another drug, this time in NASH

AZ taps Ionis for another drug, this time in NASH

Another partnered antisense candidate called AZD5312 failed to hit the mark in prostate cancer trials and was abandoned in 2016.

Latest news

  • EMA starts review of Xtandi in non-metastatic prostate cancer EMA starts review of Xtandi in non-metastatic prostate cancer

    EMA starts review of Xtandi in non-metastatic prostate cancer. The evaluation is based on positive results from the PROSPER trial. ... The EU medicines regulator has started its review of Astellas and Pfizer’s prostate cancer drug Xtandi in what looks

  • FDA approves another home genetic testing service FDA approves another home genetic testing service

    Additionally, the test can also analyse if a man is at an increased risk of developing breast or prostate cancer. ... certain individuals who may be at increased breast, ovarian or prostate cancer risk and who might not otherwise get genetic screening,

  • AbbVie’s uterine fibroids drug aces second phase III trial AbbVie’s uterine fibroids drug aces second phase III trial

    Last year, Takeda and Myovant reported positive mid-stage results with their relugolix candidate in this indication as well as endometriosis-related pain and prostate cancer.

  • AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine AZ’s Imfinzi paired with Bavarian Nordic’s CV301 vaccine

    A second phase will consist of two parallel trials with around 26 patients apiece in the two cancer indications. ... CV301 is Bavarian Nordic’s lead cancer vaccine after its much-delayed Prostvac candidate for prostate cancer failed to meet the mark in

  • AZ adds another Ionis drug in $330m kidney disease deal AZ adds another Ionis drug in $330m kidney disease deal

    Another partnered antisense candidate called AZD5312 failed to hit the mark in prostate cancer trials and was abandoned in 2016. ... The partners first started their collaboration in cancer back in 2012, and added the cardiometabolic and renal alliance

More from news
Approximately 49 fully matching, plus 299 partially matching documents found.

Latest Intelligence

  • Erectile dysfunction, constipation, vaginal dryness and other laughing matters Erectile dysfunction, constipation, vaginal dryness and other laughing matters

    Billy Connolly received the news of his diagnosis for dementia and prostate cancer on the same day:. ... And on the Wednesday I got news that I had prostate cancer and Parkinson’s disease… But when we went into the living room I went, phrrhrht, ”he

  • Deal Watch February 2017 Deal Watch February 2017

    In February, it granted North American rights to Zoladex, a goserelin acetate implant for prostate and breast cancer and benign gynaecological disorders, to US company TerSera Therapeutics. ... Licence. 358. AstraZeneca/ TerSera Therapeutics. Zoladex,

  • Deal Watch September 2016 Deal Watch September 2016

    At a lower disclosed headline value of $310m BioNTech licensed its mRNA-based cancer vaccines platform to Genentech. ... Janssen granted Tracon Pharmaceuticals the rights to develop two oncology programmes for prostate cancer and haematological

  • Deal Watch August 2016 Deal Watch August 2016

    35! Although Pfizer pointed to the $2.2bn of Xtandi sales for advanced metastatic prostate cancer, this product has been under licence to Astellas since 2009, including a US profit share ... Headline £m. Medivation (US). Pfizer (US). Company acquisition.

  • Deal Watch May 2016 Deal Watch May 2016

    The prize of course is the one marketed product in Medivation's portfolio, Xtandi [enzalutamide for the treatment of advanced prostate cancer] with sales estimated to reach $1.5bn and already ... 110. CSPC Pharmaceutical/ Watson [Allergan]. Licence.

More from intelligence
Approximately 1 fully matching, plus 37 partially matching documents found.

Latest appointments

  • Dendreon appoints new R&D lead Dendreon appoints new R&D lead

    urologists who are uniquely positioned to deliver long-term care to men with prostate cancer. ... stage prostate cancer, with the hope of curing more men of the disease.”.

  • Astellas bolsters oncology clinical development leadership Astellas bolsters oncology clinical development leadership

    breast cancer, leukaemia, lung cancer and prostate cancer. ... of Medicine and the University of Texas MD Anderson Cancer Center.

  • Astellas promotes John Demaree Astellas promotes John Demaree

    Demaree was promoted from his position as executive director of oncology marketing, where he oversaw the launch of prostate cancer drug Xtandi (enzalutamide) and promotion of lung cancer therapy Tarceva (erlotinib). ... Mark Reisenauer, senior vice

  • MDxHealth creates new global commercial team MDxHealth creates new global commercial team

    MDxHealth has created a new global commercial team to drive the launch of SelectMDx, its new prostate cancer test. ... the commercialisation of a molecular diagnostic test for prostate cancer across Europe.”.

  • Dr Hamina Patel moves from J&J to Evgen Pharma Dr Hamina Patel moves from J&J to Evgen Pharma

    She joins the firm from Johnson and Johnson, where she was director of drug development, oncology, where she helped to build a broad portfolio of indications for its cancer drug Velcade. ... interest in prostate cancer.

More from appointments
Approximately 0 fully matching, plus 11 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 8 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Blue Latitude Health

Blue Latitude Health is a creative marketing consultancy. Founded in 2003, our combination of heritage, approach and capability gives us...

Latest intelligence

No incentive for a cure
The paradox of ‘cost-effective but unaffordable’ life-saving medicines...
Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...

Infographics